Table 2.
Dependent variable, change from baseline | IADL | PSMS | ||||
---|---|---|---|---|---|---|
Percentage of variance accounted for |
R2= 0.310,p< 0.001 |
R2= 0.335,p< 0.001 |
||||
Significant predictors |
β |
95% CI (β) |
pvalue |
β |
95% CI (β) |
pvalue |
Intercept |
−10.922 |
−15.585, –6.259 |
< 0.001 |
0.419 |
−2.156, 2.995 |
0.749 |
Age at first assessment, years |
−0.041 |
−0.070, –0.011 |
0.007 |
−0.018 |
−0.036, –0.001 |
0.036 |
ADL score at baselinea |
0.521 |
0.300, 0.741 |
< 0.001 |
−0.175 |
−0.441, 0.090 |
0.196 |
MMSE score at baseline |
0.453 |
0.267, 0.640 |
< 0.001 |
−0.021 |
−0.128, 0.086 |
0.697 |
Number of medications at baseline |
|
|
ns |
−0.079 |
−0.134, –0.024 |
0.005 |
NSAIDs/Acetylsalicylic acid (no = 0, yes = 1) |
|
|
ns |
0.419 |
0.133, 0.705 |
0.004 |
Interaction terms: |
|
|
|
|
|
|
ADL baseline scorea × MMSE baseline score | −0.016 | −0.026, –0.006 | 0.002 | 0.018 | 0.005, 0.032 | 0.008 |
Gender, APOE ε4 carrier status, solitary living, age at onset (or duration of AD), years of education and the variables comparing the ChEI agents and dose were not significant.
β values are expressed per 1 unit increase for continuous variables and for the condition present in dichotomous variables
aADL = IADL or PSMS, respectively.
ChEI cholinesterase inhibitor, CI confidence interval, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal anti-inflammatory drugs, ns not significant, PSMS Physical Self-Maintenance Scale.